Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Brown (London, United Kingdom). Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials?. International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players?

Member's Comments

No comment yet.

Related content which might interest you: Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019 What new biomarkers are on the horizon for severe exacerbations? Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC Year: 2021 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Genes, mechanisms and new therapies for asthma Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Phase three studies of biologics for severe asthma: could do better? Source: Eur Respir J, 50 (3) 1701108; 10.1183/13993003.01108-2017 Year: 2017 Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 What could we learn from ongoing therapeutic trials? Source: ERS Research Seminar Year: 2015 Biomarkers of inhalation - what’s new and what is useful in smoking cessation and reduction trials? Source: Annual Congress 2003 - PG20 - Smoking reduction and smoking cessation - an update and suggestions for future studies Year: 2003